Back to School: How biopharma can reboot drug development. Access exclusive analysis here

QuatRx's Ophena meets Phase III endpoints

QuatRx (Ann Arbor, Mich.) said top-line data showed that

Read the full 92 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE